Jagiellonian University Repository

Ten years of anti-HPV vaccinations : what do we know?

pcg.skipToMenu

Ten years of anti-HPV vaccinations : what do we know?

Show full item record

dc.contributor.author Jach, Robert [SAP20001622] pl
dc.contributor.author Basta, Antoni [SAP20000267] pl
dc.contributor.author Kotarski, Jan pl
dc.contributor.author Markowska, Janina pl
dc.contributor.author Paszkowski, Tomasz pl
dc.contributor.author Dębski, Romuald pl
dc.contributor.author Rokita, Wojciech pl
dc.contributor.author Kędzia, Witold pl
dc.contributor.author Kiszka, Krystyna pl
dc.date.accessioned 2020-01-17T09:12:06Z
dc.date.available 2020-01-17T09:12:06Z
dc.date.issued 2016 pl
dc.identifier.issn 1643-8876 pl
dc.identifier.uri https://ruj.uj.edu.pl/xmlui/handle/item/139482
dc.language eng pl
dc.rights Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa *
dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/4.0/pl/legalcode pl
dc.title Ten years of anti-HPV vaccinations : what do we know? pl
dc.type JournalArticle pl
dc.description.physical 170-175 pl
dc.abstract.en Human papillomavirus (HPV) is one of the most important carcinogens in humans. Vaccines against HPV are now considered the first anti-cancer vaccinations. Since 2007, in many developed countries, there have been recommendations present for preventive vaccines against HPV. At present, the degree of implementation of these recommendations depends on a number of country-specific factors such as the health care system organization or the ways of funding. HPV vaccines are primarily to prevent the development of cervical cancer and other genital cancers. Therefore, only their long-term effectiveness can be measured, when a correspondingly large cohort of vaccinated teenagers reaches the age of the greatest incidence of these cancers. However, great care should be taken in assessing the results of vaccinations due to the possibility of misinterpretation and possible erroneous data. Undoubtedly, teenagers are the target population of HPV vaccines. However, vaccinating young sexually active women is also justified from an individual point of view. A 9-valent vaccine has been registered in the USA and in Europe - including Poland - as one of the three preventive vaccines. It is recommended to vaccinate women between 13 and 26 and men between 13 and 21, previously unvaccinated. It is also recommended to vaccinate men aged 26 years or less who have sexual relations with other men and people with reduced immunity, including HIV-positive people who have not been vaccinated previously. pl
dc.subject.en HPV pl
dc.subject.en human papillomavirus pl
dc.subject.en HPV vaccine pl
dc.description.volume 15 pl
dc.description.number 3 pl
dc.description.points 8 pl
dc.identifier.doi 10.5114/pm.2016.63497 pl
dc.identifier.eissn 2299-0038 pl
dc.title.journal Przegląd Menopauzalny pl
dc.language.container pol pl
dc.affiliation Wydział Lekarski : Klinika Endokrynologii Ginekologicznej pl
dc.affiliation Wydział Lekarski : Klinika Ginekologii i Onkologii pl
dc.subtype Article pl
dc.rights.original CC-BY-NC-SA; otwarte czasopismo; ostateczna wersja wydawcy; w momencie opublikowania; 0 pl
dc.identifier.project ROD UJ / OP pl
dc.cm.id 80253
dc.cm.date 2020-01-07
.pointsMNiSW [2016 B]: 8


Files in this item

This item appears in the following Collection(s)

Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa